OncoMatch/Clinical Trials/NCT07884110
Liver Transplantation for Colorectal Cancer
Official title: Liver Transplantation for Colorectal Cancer: a Multicenter Registry
Is NCT07884110 recruiting? Yes, currently enrolling (Oct 2026).
This is an observational study that will follow adults with stage IV colorectal cancer whose disease has spread only to the liver (not to other organs) and who are undergoing a liver transplant as part of their cancer treatment. Liver transplantation is being offered as a potentially curative option for patients whose liver metastases cannot be surgically removed. Researchers will review participants' medical records for up to 5 years after transplant to understand how this treatment affects survival, cancer recurrence, and safety. Participants will also be asked to complete a quality-of-life questionnaire (EORTC QLQ-C30). Taking part in this study does not involve any additional tests, visits, or procedures beyond the standard care participants would otherwise receive.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: BRAF wild-type
BRAF wild-type
Required: MSI stable
microsatellite stable (MSS)
Excluded: BRAF mutation
BRAF-mutated tumor
Excluded: MSI instability-high
Microsatellite instability-high (MSI-H) tumor
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Radiological and biomarker (CEA) response to treatment after at least 6 months of systemic therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07884110 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Does this trial require BRAF?
Yes, BRAF wild-type is a required biomarker for enrollment.
Does this trial require MSI?
Yes, MSI stable is a required biomarker for enrollment.
Are patients with BRAF alterations eligible?
No. BRAF mutation is an exclusion criterion.
Are patients with MSI alterations eligible?
No. MSI instability-high is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages